TRAF3IP2 and heart disorder: The peptide ACT-1, targeting the carboxyl tail region of CX43 shows exciting possibility in phase 3 clinical trials in wound healing and in tailored targeting of cardiac disease by Prof Rob Gourdie and colleagues [181,182] (https://firststringresearch.com/).